Cutting-Edge

Mutation-agnostic antivirals and vaccines against influenza viruses, coronaviruses and potentially other viruses and cancers

Novel Product

VaxDome technology delivers a low dose of a selected influenza virus strain attenuated with a neuraminidase inhibitor that allows sequestration of the virus and training of the immune system to counter a broad spectrum of viral infections by eliciting trained immunity in conjunction with adaptive immunity in a sustainable anti-agnostic manner.

=

+

Zanamivir
(binds to NA)

Influenza

zIFV

Packaged in an easy-to-use intranasal syringe

HA

NA

HA - Hemagglutinin
NA - Neuraminidase

Anti-Dogmatic Mechanisms

zIFV blocks influenza virus entry (partially), budding release (totally) and sequesters viruses within cells

Normal influenz virus infection process

zIFV infection

zIFV immunization generates tertiary lymphoid structures in lung tissue
zIFV infection only requires ~10 infectious units in a single dose for immunization